CN102596223A - 杀肿瘤的、杀菌的、或杀病毒的巨噬细胞的激活 - Google Patents

杀肿瘤的、杀菌的、或杀病毒的巨噬细胞的激活 Download PDF

Info

Publication number
CN102596223A
CN102596223A CN2010800374048A CN201080037404A CN102596223A CN 102596223 A CN102596223 A CN 102596223A CN 2010800374048 A CN2010800374048 A CN 2010800374048A CN 201080037404 A CN201080037404 A CN 201080037404A CN 102596223 A CN102596223 A CN 102596223A
Authority
CN
China
Prior art keywords
gcmaf
macrophages
immobilized
acetylgalactosaminidase
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800374048A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·肯尼萨维奇
罗伯特·希尔维兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102596223A publication Critical patent/CN102596223A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN2010800374048A 2009-08-22 2010-08-23 杀肿瘤的、杀菌的、或杀病毒的巨噬细胞的激活 Pending CN102596223A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23608809P 2009-08-22 2009-08-22
US61/236,088 2009-08-22
PCT/US2010/046356 WO2011028485A2 (en) 2009-08-22 2010-08-23 Tumoricidal, bactericidal, or viricidal macrophage activation

Publications (1)

Publication Number Publication Date
CN102596223A true CN102596223A (zh) 2012-07-18

Family

ID=43649882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800374048A Pending CN102596223A (zh) 2009-08-22 2010-08-23 杀肿瘤的、杀菌的、或杀病毒的巨噬细胞的激活

Country Status (8)

Country Link
US (1) US20110123591A1 (enExample)
EP (1) EP2467154A4 (enExample)
CN (1) CN102596223A (enExample)
AU (1) AU2010289901A1 (enExample)
CA (1) CA2771900A1 (enExample)
IN (1) IN2012DN02200A (enExample)
TW (1) TW201113372A (enExample)
WO (1) WO2011028485A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601606A (zh) * 2017-11-29 2020-08-28 菲格内有限责任公司 用于活化的成纤维细胞与免疫细胞的相互作用及其用途
CN114854579A (zh) * 2022-04-13 2022-08-05 武汉大学 可用于临床的外周血特定亚群细胞外囊泡分离平台
CN115443329A (zh) * 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547280B (zh) * 2011-04-07 2017-06-09 艾弗兰纳特有限公司 用于药物组合物的巨噬细胞活化因子
WO2014113641A1 (en) * 2013-01-18 2014-07-24 Kline Ellis Selective glycosidase regimen for immune programming and treatment of cancer
RU2717218C1 (ru) * 2019-08-07 2020-03-18 Зайцева Инга Николаевна Способ торможения роста подкожного трансплантата экспериментальной глиобластомы человека u-87, перевитого иммунодефицитным мышам nu/j

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1510147A (zh) * 1995-06-07 2004-07-07 ������ɽ���� 测定α-N-乙酰氨基半乳糖苷酶活性的方法
US20080275376A1 (en) * 1999-11-20 2008-11-06 Mark Douglas Howell Method for enhancing immune responses in mammals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050103712A1 (en) * 2003-11-13 2005-05-19 Voyce Brian D. Methods and devices for treating severe peripheral bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1510147A (zh) * 1995-06-07 2004-07-07 ������ɽ���� 测定α-N-乙酰氨基半乳糖苷酶活性的方法
US20080275376A1 (en) * 1999-11-20 2008-11-06 Mark Douglas Howell Method for enhancing immune responses in mammals

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601606A (zh) * 2017-11-29 2020-08-28 菲格内有限责任公司 用于活化的成纤维细胞与免疫细胞的相互作用及其用途
US12233094B2 (en) 2017-11-29 2025-02-25 Spinalcyte, Llc Interaction of fibroblasts and immune cells for activation and uses thereof
CN115443329A (zh) * 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
US12485174B2 (en) 2019-06-27 2025-12-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-activated macrophages, compositions, and uses thereof
CN114854579A (zh) * 2022-04-13 2022-08-05 武汉大学 可用于临床的外周血特定亚群细胞外囊泡分离平台

Also Published As

Publication number Publication date
IN2012DN02200A (enExample) 2015-08-21
WO2011028485A3 (en) 2011-07-14
TW201113372A (en) 2011-04-16
CA2771900A1 (en) 2011-03-10
WO2011028485A2 (en) 2011-03-10
AU2010289901A1 (en) 2012-03-15
EP2467154A4 (en) 2013-03-27
EP2467154A2 (en) 2012-06-27
US20110123591A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
Lu et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Yu et al. Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy
Umemoto et al. Constitutive plasmacytoid dendritic cell migration to the splenic white pulp is cooperatively regulated by CCR7-and CXCR4-mediated signaling
JP7432624B2 (ja) Ｎａｄ＋及び／又はｎａｄ＋阻害剤及び／又はｎａｄ＋アゴニストの使用及びその配合剤
CN102596223A (zh) 杀肿瘤的、杀菌的、或杀病毒的巨噬细胞的激活
US20240141008A1 (en) Therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
Prutchi‐Sagiv et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?
CN104470535A (zh) 用于治疗肿瘤的方法
EP4435101A1 (en) Membrane surface protein containing gpi anchor region
EP4321536A1 (en) Bispecific antibody and use thereof
Jin et al. Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system
CN120769904A (zh) 表达膜结合细胞因子的肿瘤浸润淋巴细胞
EP1753452B1 (en) A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor
WO2022221183A1 (en) Fournierella extracellular vesicle preparations
CN118652355B (zh) 靶向psma的嵌合抗原受体及其修饰的细胞和应用
EP4628071A1 (en) Targeting nanoscale particle, targeting cell, preparation method therefor, and use thereof
CN111182918A (zh) 用于激活免疫细胞的方法
Zhang et al. Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles
TWI721352B (zh) 含有ｇｍ３神經節苷酯作為免疫調節劑之奈米粒子
CN118715239A (zh) 包含多亚基细胞因子的双细胞因子融合蛋白
WO2023167842A2 (en) Acoustic enrichment of adoptive cell transfers
Steenbrugge et al. Xenogeneic equine stem cells activate anti-tumor adaptive immunity in a 4T1-based intraductal mouse model for triple-negative breast cancer: proof-of-principle
Fukuta et al. Cell therapies against brain tumors: Clinical development and emerging prospects
CA3187578A1 (en) Method of treating aml subtypes using arginine-depleting agents
CN109793889B (zh) 一种肿瘤疫苗及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120718